Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

Respiratory Medicine

Volumn 95, Issue 1, 2001, Pages 83-89

  Price, D B ^a   Ben Joseph, R H ^b   Zhang, Q ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; Cost; Montelukast; Salmeterol; U.K.

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONTELUKAST; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CONTROL; DRUG COST; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM;

EID: 0034935739     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2000.1006     Document Type: Article

References (19)

1. Global strategy for asthma management and prevention NHLBI/WHO workshop report
2. Asthma
3. The costs of asthma
4. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma
5. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
6. Montelukast added to inhaled beclomethasone in treatment of asthma
7. Leukotriene modifiers as novel therapeutics in asthma
8. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
9. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment
10. How should cost data in pragmatic randomized trials be analyzed
11. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction
12. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol
13. Evaluation of the long-term effect of montelukast in adult (≥15 years) and pediatric (6- to 14- years) patients
14. Inhaled steroids and the risk of hospitalization for asthma
15. Impact of an interest in asthma on prescribing costs in general practice
16. The cost of asthma; an it be reduced?
17. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease
18. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients
19. Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: Retrospective study of computerised general practice records